PDCD1 and neoplasm: Importantly, niraparib-induced alteration of the tumor microenvironment favored its combination with anti-PD-1 therapy, in which niraparib and anti-PD-1 demonstrated synergistic antitumor activity in both BRCA mutant and BRCA wild-type tumor models.